Read on Twitter
I don't see a ton of attention towards healthcare companies from FinTwit compared to tech companies but $CRSP has a webcast on Dec. 9th that could provide a tailwind for the stock @PrivateSeptum https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-host-investor-webcast-review-data
It's been about a year since they announced positive results in genetic editing a beta thalassemia and a sickle cell disease patient. I'm expecting further positive updates https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-positive-safety-and?utm_campaign=Sunday%20Newsletter&utm_source=hs_email&utm_medium=email&utm_content=79851375&_hsmi=79851375
Besides being effective, this one-time treatment allows for patients, healthcare providers, and healthcare payers to save an enormous amount of resources by preventing morbidity and mortality.
In the coming years, we will see Centers for Medicare and Medicaid Services approve high price values for one-time treatments due to this -- something that I do not believe is priced into $CRSP while I do believe their extensive intellectual property is
